Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 19/20 | 0.41 |
| ▸ | THRB | P10828 | 19/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21840344 | 0.87 | THRA (0.44) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840326 | 0.83 | THRB (0.53) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840325 | 0.82 | THRA (0.62) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840346 | 0.81 | THRA (0.41) | THRATHRB | |
| SCHEMBL21840294 | 0.81 | THRA (0.43) | THRATHRB | |
| SCHEMBL21940320 | 0.78 | THRA (0.42) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840284 | 0.78 | THRA (0.49) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21939568 | 0.77 | THRA (0.42) | THRATHRB | |
| SCHEMBL28646663 | 0.74 | THRB (0.45) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840352 | 0.74 | THRA (0.41) | THRATHRBCYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3863635-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-112839655-A | Thyroid hormone receptor beta agonist compounds | 拓臻股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885CYP2C9 3737/4885 |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885CYP2C9 3737/4885 |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, LIPC | THRA 25/4885THRB 19/4885CYP2C9 3141/4885 |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885CYP2C9 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.